Could a 4-Week steroid course be safer for vasculitis patients?

NCT ID NCT06983821

Recruiting now Disease control Sponsor: Ottawa Hospital Research Institute Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 3 trial is testing whether a 4-week low-dose steroid regimen, given alongside standard drugs like rituximab or cyclophosphamide, is safer and as effective as the usual longer steroid treatment for ANCA vasculitis with severe kidney problems. The study will enroll 36 people with newly diagnosed or relapsed disease. The goal is to reduce serious infections while still controlling the disease.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Prednisone (a steroid) given with standard drugs like rituximab or cyclophosphamide
What this could lead to: If successful, this could lead to a safer, shorter steroid treatment for ANCA vasculitis, reducing serious infections while still controlling the disease.
What could go wrong: This is a small pilot phase (36 participants) testing feasibility, so results may not apply broadly. The low steroid dose might not control the disease as well as standard care, risking relapse.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GRANULOMATOSIS WITH POLYANGIITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

anti-neutrophil cytoplasmic antibody-associated vasculitis granulomatosis with polyangiitis microscopic polyangiitis vasculitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GRANULOMATOSIS WITH POLYANGIITIS MICROSCOPIC POLYANGIITIS (MPA)

Contacts and locations

Locations

St-Joseph's Hospital
NOT_YET_RECRUITING

Hamilton, Ontario, Canada
The Ottawa Hospital
RECRUITING

Ottawa, Ontario, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.